Latest research on Sevelamer

Sevelamer is a phosphate binding drug used to prevent hyperphosphataemia in patients with chronic renal failure. When taken with meals, sevelamer binds to dietary phosphate and prevents its absorption. It is marketed by Genzyme under the trade name Renagel.

Sevelamer side effects

Sevelamer carbonate may cause gastrointestinal adverse events including nausea, vomiting, dyspepsia, abdominal pain, and changes in bowel habits. [source, 2016]
Serum phosphate significantly decreased in all groups except that receiving sucroferric oxyhydroxide 1.25 g/day; in particular, the 5 g/day and 7.5 g/day dosages were as efficacious as 4.8 g/day of Sevelamer hydrochloride. [source, 2016]
The side effects more often observed in the sucroferric oxyhydroxide group were mild and transient diarrhea, discolored feces, and hyperphosphatemia; patients treated with Sevelamer mainly experienced constipation and nausea. [source, 2016]
Simultaneously, there has been an increase in utilization of non-calcium phosphate binders and several new resin-based products that have been approved by the Food and Drug Administration (FDA) for this indication, including Sevelamer hydrochloride, a non-absorbed synthetic polymer [6–9]. [source, 2016]
However, there is little information regarding gastrointestinal ulceration as a side effect; only a report of Sevelamer crystals isolated from the gastrointestinal tracts of patients with symptoms of gastrointestinal distress have been identified in the literature [15]. [source, 2016]
We, therefore, favor that Sevelamer was the primary cause for the rectal ulcers. [source, 2016]
The Serious:Non-serious ratio for eldecalcitol, peginterferon alpha-2a, and Sevelamer hydrochloride increased steadily throughout the study period. [source, 2015]
The High prominence:Low prominence ratio for only Sevelamer hydrochloride showed a steady decrease during the study period. [source, 2015]
The High frequency:Low frequency ratio for peginterferon alpha-2a and Sevelamer hydrochloride decreased steadily throughout the study period (Fig 5). [source, 2015]
The Sevelamer hydrochloride package insert was updated 4 months after initial marketing to include “intestinal perforation” in the Important Precautions and Clinically Significant Adverse Reactions sections, and this could have increased ADR reporting during the EPPV period. [source, 2015]